The RED-C Study for Patients with Liver Cirrhosis and Medically Controlled Ascites

The RED-C study is designed to assess how well Rifaximin soluble solid dispersion tablets work to delay hepatic encephalopathy (confusion due to liver cirrhosis) in patients with liver cirrhosis related to any kind of liver disease. Patients will need to attend regular research visits at the Rush downtown campus.

In order to participate you must meet the following criteria:

• Have been diagnosed with liver cirrhosis with medically controlled ascites. 

You will be excluded from the study if any of the following criteria apply to you:

• Have experienced an episode of hepatic encephalopathy in the past.
• Have taken or be taking rifaximin 550 mg and/or lactulose for a suspected hepatic encephalopathy episode.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.